<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02073864</url>
  </required_header>
  <id_info>
    <org_study_id>Yale Neuro TAVR</org_study_id>
    <nct_id>NCT02073864</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Neuro-embolic Consequences of TAVR</brief_title>
  <official_title>Neurological Complications of Contemporary Unprotected TAVR (Yale Neuro TAVR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Keystone Heart</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Keystone Heart</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, multi-center study to evaluate the neuro-embolic consequences of Transcatheter&#xD;
      Aortic Valve Replacement (TAVR)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, multi-center study enrolling a minimum of 20 up to a maximum of 80 patients at&#xD;
      up to six investigational sites in the United States and European Union. Patients meeting&#xD;
      eligibility criteria for TAVR will be enrolled to undergo diffusion-weighted MRI brain&#xD;
      imaging pre-procedure (optional) and post-procedure and neuropsychological testing pre- and&#xD;
      post-procedure, and at 30 days of follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of diffusion-weighted MRI lesions following TAVR without cerebral embolic protection</measure>
    <time_frame>1 week post procedure</time_frame>
    <description>Number of new diffusion-weighted MRI lesions</description>
  </primary_outcome>
  <enrollment type="Actual">46</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients indicated for TAVR procedure&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient must be ≥18 years of age.&#xD;
&#xD;
          -  Patient meets indications for TAVR procedure.&#xD;
&#xD;
          -  The patient is willing to comply with protocol-specified follow-up evaluations.&#xD;
&#xD;
          -  The patient, or legally authorized representative, has been informed of the nature of&#xD;
             the study, agrees to its provisions and has provided written informed consent,&#xD;
             approved by the appropriate Institutional Review Board (IRB) or Ethics Committee (EC).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing TAVR via the trans-axillary, subclavian, or direct aortic route&#xD;
&#xD;
          -  Pregnant or nursing subjects and those who plan pregnancy in the period up to 1 year&#xD;
             following index procedure. Female subjects of child-bearing potential must have a&#xD;
             negative pregnancy test done within 7 days prior to index procedure per site standard&#xD;
             test.&#xD;
&#xD;
          -  Patients with known diagnosis of acute myocardial infarction (AMI) within 72 hours&#xD;
             preceding the index procedure (according to definition) or AMI &gt;72 hours preceding the&#xD;
             index procedure, in whom creatine kinase and creatine kinase have not returned to&#xD;
             within normal limits at the time of procedure.&#xD;
&#xD;
          -  Patients who are currently experiencing clinical symptoms consistent with new onset&#xD;
             AMI, such as nitrate-unresponsive prolonged chest pain.&#xD;
&#xD;
          -  Patients with impaired renal function (estimated Glomerular Filtration Rate [Estimated&#xD;
             Glomerular Filtration Rate] &lt;30, calculated from serum creatinine by the&#xD;
             Cockcroft-Gault formula).&#xD;
&#xD;
          -  Patients with a platelet count of &lt;100.000 cells/mm³ or &gt; 700.000 cells/mm³ or a white&#xD;
             blood cell&lt; 3000 cells/mm³ within 7 days prior to index procedure or per standard&#xD;
             local practice.&#xD;
&#xD;
          -  Patients with a history of bleeding diathesis or coagulopathy or patients in whom&#xD;
             anti-platelet and/or anticoagulant therapy is contraindicated, or who will refuse&#xD;
             transfusion.&#xD;
&#xD;
          -  Patients who have received any organ transplant or are on a waiting list for any organ&#xD;
             transplant.&#xD;
&#xD;
          -  Patients with known other medical illness or known history of substance abuse that may&#xD;
             cause non-compliance with the protocol, confound the data interpretation or is&#xD;
             associated with a life expectancy of less than one year.&#xD;
&#xD;
          -  Patients with known hypersensitivity or contraindication to aspirin,&#xD;
             heparin/bivalirudin, clopidogrel/ticlopidine, nitinol, stainless steel alloy, and/or&#xD;
             contrast sensitivity that cannot be adequately pre-medicated.&#xD;
&#xD;
          -  Patients with a history of a stroke or transient ischemic attack (TIA) within the&#xD;
             prior 6 months.&#xD;
&#xD;
          -  Patients with an active peptic ulcer or history of upper gastrointestinal (GI)&#xD;
             bleeding within the prior 6 months.&#xD;
&#xD;
          -  Patients presenting with cardiogenic shock.&#xD;
&#xD;
          -  Patients with documented friable or mobile atherosclerotic plaque in the aortic arch.&#xD;
&#xD;
          -  Patients with contraindication to cerebral MRI.&#xD;
&#xD;
          -  Patients with any other cardiovascular procedure prior to TAVR&#xD;
&#xD;
          -  Patients with severe aortic arch atheroma visible on CT scan&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandra Lansky, Md.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale Cardiovascular Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Hospital of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>Fort Lee</city>
        <state>New Jersey</state>
        <zip>07024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Francis Hospital</name>
      <address>
        <city>Roslyn</city>
        <state>New York</state>
        <zip>11576</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Heart Hospital Baylor Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>February 23, 2014</study_first_submitted>
  <study_first_submitted_qc>February 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2014</study_first_posted>
  <last_update_submitted>August 26, 2015</last_update_submitted>
  <last_update_submitted_qc>August 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic valve stenosis, stenosis, intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

